Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:DVAX
CUSIP26815810
Phone510-848-5100
Debt
Debt-to-Equity Ratio0.76
Current Ratio8.87
Quick Ratio8.67
Price-To-Earnings
Trailing P/E Ratio-7.28
Forward P/E Ratio-5.27
P/E GrowthN/A
Sales & Book Value
Annual Sales$330,000.00
Price / Sales2,390.95
Cash FlowN/A
Price / CashN/A
Book Value$3.29 per share
Price / Book3.83
Profitability
EPS (Most Recent Fiscal Year)($1.73)
Net Income$-95,150,000.00
Net Margins-8,570.06%
Return on Equity-72.31%
Return on Assets-50.92%
Miscellaneous
Employees170
Outstanding Shares62,620,000
Market Cap$832.79 million
Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions
What is Dynavax Technologies' stock symbol?
Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."
How were Dynavax Technologies' earnings last quarter?
Dynavax Technologies Co. (NASDAQ:DVAX) announced its earnings results on Monday, August, 6th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.01. The biopharmaceutical company earned $1.25 million during the quarter, compared to analyst estimates of $1.88 million. Dynavax Technologies had a negative return on equity of 72.31% and a negative net margin of 8,570.06%. Dynavax Technologies's revenue for the quarter was up 1094.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.41) earnings per share. View Dynavax Technologies' Earnings History.
When is Dynavax Technologies' next earnings date?
What price target have analysts set for DVAX?
4 Wall Street analysts have issued 1 year price objectives for Dynavax Technologies' stock. Their forecasts range from $25.00 to $30.00. On average, they expect Dynavax Technologies' share price to reach $27.50 in the next twelve months. This suggests a possible upside of 118.3% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.
What is the consensus analysts' recommendation for Dynavax Technologies?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.
What are Wall Street analysts saying about Dynavax Technologies stock?
Here are some recent quotes from research analysts about Dynavax Technologies stock:
- 1. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (8/9/2018)
- 2. Cantor Fitzgerald analysts commented, "HEPLISAV-B Launched. Dynavax reported that HEPLISAV-B, a two-dose hepatitis B vaccine, has been launched in the U.S. with a 60-person field sales team covering 75% of the market. HEPLISAV-B was recommended by the CDC for use in the vaccination of adults, which the company believes is critical to drive broad insurance coverage and adoption. By now, 100% of Medicare lives, 74% of commercially-insured lives, and 60% of lives covered under Medicaid plans have HEPLISAV-B specific CPT codes, referencing the correct price. In the first two months following launch, the sales team met two-thirds of the targeted key accounts, corresponding to more than half of the addressable market. The sales cycle is estimated to be 6-8 weeks at this stage. As previously reported, the company has a drug supply of over 250,000 vials, with an additional 750,000 vials worth of raw material." (5/8/2018)
- 3. Cowen Inc analysts commented, "Dynavax reported a Q3 net loss of $22.1MM and ended the quarter with $192MM in." (11/3/2017)
Are investors shorting Dynavax Technologies?
Dynavax Technologies saw a increase in short interest in the month of July. As of July 31st, there was short interest totalling 10,615,838 shares, an increase of 15.3% from the July 13th total of 9,205,482 shares. Based on an average trading volume of 1,249,567 shares, the short-interest ratio is currently 8.5 days. Approximately 17.2% of the shares of the stock are sold short. View Dynavax Technologies' Current Options Chain.
Who are some of Dynavax Technologies' key competitors?
Some companies that are related to Dynavax Technologies include Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Amicus Therapeutics (FOLD), Ironwood Pharmaceuticals (IRWD), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Emergent Biosolutions (EBS), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN), Global Blood Therapeutics (GBT) and Myokardia (MYOK).
Who are Dynavax Technologies' key executives?
Dynavax Technologies' management team includes the folowing people:
- Mr. Eddie Gray, CEO & Director (Age 59)
- Dr. Dennis A. Carson Ph.D., M.D., Co-Founder, Director & Member of Scientific Advisory Board (Age 71)
- Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 66)
- Mr. David F. Novack, Sr. VP of Operations & Quality (Age 56)
- Dr. Robert L. Coffman, Chief Scientific Officer & Sr. VP (Age 71)
Has Dynavax Technologies been receiving favorable news coverage?
Media stories about DVAX stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dynavax Technologies earned a news and rumor sentiment score of 0.11 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.87 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Dynavax Technologies.
Who are Dynavax Technologies' major shareholders?
Dynavax Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.53%), Senvest Management LLC (3.73%), Eagle Asset Management Inc. (3.69%), PointState Capital LP (3.02%), Federated Investors Inc. PA (2.66%) and Carillon Tower Advisers Inc. (2.63%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Michael S Ostrach, Robert Coffman and Robert Janssen. View Institutional Ownership Trends for Dynavax Technologies.
Which institutional investors are selling Dynavax Technologies stock?
DVAX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., GMT Capital Corp, Federated Investors Inc. PA, First Trust Advisors LP, Bank of New York Mellon Corp, Fisher Asset Management LLC, Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold Dynavax Technologies company stock in the last year include David F Novack, David Louis Johnson, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.
Which institutional investors are buying Dynavax Technologies stock?
DVAX stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., PointState Capital LP, Carillon Tower Advisers Inc., Senvest Management LLC, Chicago Capital LLC, Bank of America Corp DE, BlackRock Inc. and Northpointe Capital LLC. View Insider Buying and Selling for Dynavax Technologies.
How do I buy shares of Dynavax Technologies?
Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dynavax Technologies' stock price today?
One share of DVAX stock can currently be purchased for approximately $12.60.
How big of a company is Dynavax Technologies?
Dynavax Technologies has a market capitalization of $832.79 million and generates $330,000.00 in revenue each year. The biopharmaceutical company earns $-95,150,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. Dynavax Technologies employs 170 workers across the globe.
How can I contact Dynavax Technologies?
Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]
MarketBeat Community Rating for Dynavax Technologies (NASDAQ DVAX)
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
